Akeso, Inc. is a pharmaceutical company based in China with a Risk Rating Score of 32.3, indicating a high-risk assessment. The company focuses on research, development, production, and commercialization of biopharmaceutical products. With over 30 drugs in its pipeline for diseases such as cancers, autoimmune diseases, inflammation, and metabolic disorders, Akeso is known for its innovative approach to healthcare. The majority of its revenue is generated in Mainland China. With a strong emphasis on ESG principles, Akeso Inc. is committed to sustainability and governance practices in the pharmaceutical industry.